Investigational drug · Phase 2
DZD6008
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "DZD6008"
First trial start
2025
Jul 16, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DZD6008", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- Non Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "DZD6008" as an intervention, largest first.
Dizal PharmaceuticalsIndustry
NCT06813365 · 300 participants (planned) · Start Jun 12, 2024 · Primary completion Oct 30, 2027
Drug: DZD6008 · For: Nonsmall-cell Lung Cancer
Sites: Beijing, China
- Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)Pivotal-lookingRecruiting
Dizal PharmaceuticalsIndustry
NCT07079475 · 220 participants (planned) · Start Jul 30, 2025 · Primary completion Jun 2028
Drug: DZD6008; Sunvozertinib and 1 more · For: Non-Small Cell Lung Cancer
Sites: Beijing, China; Guangzhou, China; Harbin, China · 14 sites in all
- DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)Pivotal-lookingRecruiting
Dizal PharmaceuticalsIndustry
NCT07070440 · 180 participants (planned) · Start Jul 16, 2025 · Primary completion Jun 2027
Drug: DZD6008; Pemetrexed and 2 more · For: Non Small Cell Lung Cancer
Sites: Shanghai, China
- A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)Pivotal-lookingRecruiting
Dizal PharmaceuticalsIndustry
NCT06905197 · 140 participants (planned) · Start May 13, 2025 · Primary completion Sep 2027
Drug: DZD6008; Sunvozertinib · For: Non Small Cell Lung Cancer
Sites: New York, New York; Fairfax, Virginia; Blacktown, Australia · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.